UBS initiated coverage of Rohto Pharmaceutical (RPHCF) with a Neutral rating and 2,600 yen price target The firm sees a balanced risk/reward at the stock’s current valuation, noting the company’s core business growth has slowed.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF:
- Rohto Pharmaceutical Reports Strong Growth in Latest Earnings
- Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
- Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
- Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion
- Rohto Pharmaceutical’s New Study: A Potential Game-Changer for Heart Disease Treatment?